{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    44,
    45,
    50,
    51,
    52,
    53,
    54,
    56,
    58,
    60,
    65,
    90
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "Date of subject randomization",
        "anchorType": "Randomization",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 40,
        "sourceText": "day of randomization",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_llm_1",
        "definition": "Baseline",
        "anchorType": "Baseline",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 50,
        "sourceText": "Change from baseline in BCVA at Week 24",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_2",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 20,
        "sourceText": "screening period",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_3",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 10,
        "sourceText": "Informed Consent",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_4",
        "definition": "procedure",
        "anchorType": "Custom",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 100,
        "sourceText": "procedure",
        "encounterId": null,
        "activityId": null
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_5",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "P24D",
        "endOffset": "P72D",
        "sourceText": "Weeks 24 to 72"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "startOffset": "P24D",
        "endOffset": "P72D",
        "sourceText": "Week 24 through Week 72"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "startOffset": "P24D",
        "endOffset": "P72D",
        "sourceText": "Week 24 \nthrough Week 72"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "startOffset": "P24D",
        "endOffset": "P72D",
        "sourceText": "Week \n24 through Week 72"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "startOffset": "P24D",
        "endOffset": "P68D",
        "sourceText": "Week 24 through \nWeek 68"
      },
      {
        "id": "rep_window_14",
        "type": "Continuous",
        "startOffset": "P24D",
        "endOffset": "P68D",
        "sourceText": "Week 24 through Week 68"
      },
      {
        "id": "rep_window_15",
        "type": "Continuous",
        "startOffset": "P24D",
        "endOffset": "P72D",
        "sourceText": "Week 24 to \nWeek 72"
      },
      {
        "id": "rep_window_17",
        "type": "Continuous",
        "startOffset": "P24D",
        "endOffset": "P72D",
        "sourceText": "Week 24 through \nWeek 72"
      },
      {
        "id": "rep_window_28",
        "type": "Continuous",
        "startOffset": "P24D",
        "endOffset": "P68D",
        "sourceText": "Week 24 \nthrough Week 68"
      },
      {
        "id": "rep_window_29",
        "type": "Continuous",
        "startOffset": "P24D",
        "endOffset": "P68D",
        "sourceText": "Weeks 24 through 68"
      },
      {
        "id": "rep_window_31",
        "type": "Continuous",
        "startOffset": "P24D",
        "endOffset": "P72D",
        "sourceText": "from Week 24 to \nWeek 72"
      },
      {
        "id": "rep_window_32",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_37",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_40",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_llm_1",
        "type": "Cycle",
        "startOffset": "P0D",
        "endOffset": "P28D",
        "interval": "P28D",
        "minObservations": 1,
        "exitCondition": "null",
        "sourceText": "missed mandatory pharmacokinetic, pharmacodynamic, or anti-drug antibody samples may be obtained at the next scheduled visit the patient attends"
      },
      {
        "id": "rep_llm_2",
        "type": "Interval",
        "startOffset": "P0D",
        "endOffset": "null",
        "interval": "P4W",
        "minObservations": 1,
        "exitCondition": "Algorithm for IxRS-Determined Faricimab Personalized Treatment Interval",
        "sourceText": "Algorithm for IxRS-Determined Faricimab Personalized Treatment Interval Dosing Intervals"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "RANDOMIZATION",
          "TREATMENT",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study",
          "Week 24"
        ],
        "sourceText": "[{'condition': 'Failure to meet inclusion/exclusion criteria', 'path': ['SCREENING', 'RE-SCREENING']}, {'condition': 'Adverse Event or Study Treatment Discontinuation', 'path': ['EARLY_TERMINATION', 'SAFETY_FOLLOW_UP']}, {'condition': 'Participation in optional substudy', 'path': ['EXPLORATORY_SUBSTUDY']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Plasma Sample",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "SINGLE signals: 3"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 9"
      },
      {
        "activityId": "Concomitant Medication",
        "executionType": "Single",
        "rationale": "SINGLE signals: 4"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Dosing",
        "executionType": "Recurring",
        "rationale": "EPISODE signals: 2; RECURRING signals: 3"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Window",
        "rationale": "WINDOW signals: 2; SINGLE signals: 1"
      },
      {
        "activityId": "Primary Efficacy Assessment",
        "executionType": "Single",
        "rationale": "The primary efficacy objective is evaluated at a specific primary endpoint timepoint."
      },
      {
        "activityId": "Pharmacokinetic (PK) Sampling",
        "executionType": "Recurring",
        "rationale": "Protocol states missed PK samples may be obtained at the next scheduled visit, indicating a recurring collection schedule."
      },
      {
        "activityId": "Anti-drug Antibody (ADA) Sampling",
        "executionType": "Recurring",
        "rationale": "Protocol indicates ADA samples are obtained at scheduled visits throughout the study."
      },
      {
        "activityId": "National Eye Institute 25-Item Visual Functioning Questionnaire (NEI VFQ-25)",
        "executionType": "Recurring",
        "rationale": "Administration of the questionnaire is clarified as a repeated assessment during the trial."
      },
      {
        "activityId": "Investigational Medicinal Product Temperature Monitoring",
        "executionType": "Window",
        "rationale": "Sites must confirm temperature conditions were maintained during the transit window from shipment to arrival."
      },
      {
        "activityId": "Pregnancy Notification",
        "executionType": "Episode",
        "rationale": "Conditional workflow where the patient must inform the investigator only if the event (pregnancy) occurs."
      },
      {
        "activityId": "Informed Consent",
        "executionType": "Single",
        "rationale": "One-time activity performed prior to study participation."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "a. The screening and Day 1 (randomization) visits may occur as a combined visit if all assessments are completed and evaluated within 2 business days.",
        "footnoteId": "fn_1",
        "structuredCondition": "visit.combine(Screening, Day1) IF duration(Screening, Day1) <= P2D",
        "appliesToActivityIds": [
          "Screening Visit",
          "Day 1 Visit"
        ],
        "sourceText": "a. The screening and Day 1 (randomization) visits may occur as a combined visit if all assessments a"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_after",
        "text": "b. The Day 7 visit should take place 7 days after the Day 1 visit (e.g., if the Day 1 visit takes place on a Wednesday, the Day 7 visit would take place on the following Wednesday).",
        "footnoteId": "fn_2",
        "structuredCondition": "visit.offset(Day7, Day1, P7D)",
        "appliesToActivityIds": [
          "Day 7 Visit"
        ],
        "sourceText": "b. The Day 7 visit should take place 7 days after the Day 1 visit (e.g., if the Day 1 visit takes pl"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_before",
        "text": "c. Patients who discontinue from the study early (prior to the final study visit at Week 72) but have not withdrawn consent should return for an early termination visit after a minimum of 28 days have elapsed following their final study treatment.",
        "footnoteId": "fn_3",
        "structuredCondition": "visit.earlyTermination() IF duration(lastTreatment, current) >= P28D",
        "appliesToActivityIds": [
          "Early Termination Visit"
        ],
        "sourceText": "c. Patients who discontinue from the study early (prior to the final study visit at Week 72) but hav"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_before",
        "text": "d. Informed consent must be administered and documented before any study-specific screening procedure is performed...",
        "footnoteId": "fn_4",
        "structuredCondition": "activity.before(InformedConsent, anyScreeningProcedure)",
        "appliesToActivityIds": [
          "Informed Consent",
          "Screening Procedures"
        ],
        "sourceText": "d. Informed consent must be administered and documented before any study-specific screening procedur"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "e. Medical history, including clinically significant diseases, chronic and ongoing conditions...",
        "footnoteId": "fn_5",
        "structuredCondition": "data.include(clinicallySignificantDiseases, chronicConditions)",
        "appliesToActivityIds": [
          "Medical History"
        ],
        "sourceText": "e. Medical history, including clinically significant diseases, chronic and ongoing conditions..."
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "f. A targeted physical examination should include an evaluation of the head, ears, nose, and throat.",
        "footnoteId": "fn_6",
        "structuredCondition": "procedure.scope(HENT)",
        "appliesToActivityIds": [
          "Targeted Physical Examination"
        ],
        "sourceText": "f. A targeted physical examination should include an evaluation of the head, ears, nose, and throat."
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "g. Vital signs include measurement of temperature, respiratory rate, pulse rate, and systolic and diastolic blood pressure.",
        "footnoteId": "fn_7",
        "structuredCondition": "procedure.components(temp, rr, hr, sbp, dbp)",
        "appliesToActivityIds": [
          "Vital Signs"
        ],
        "sourceText": "g. Vital signs include measurement of temperature, respiratory rate, pulse rate, and systolic and di"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "timing_before",
        "text": "h. To be administered by the masked site staff (except for the BCVA examiner) before the patient receives any information on disease status...",
        "footnoteId": "fn_8",
        "structuredCondition": "activity.before(Questionnaires, diseaseStatusUpdate)",
        "appliesToActivityIds": [
          "Patient Reported Outcomes",
          "Questionnaires"
        ],
        "sourceText": "h. To be administered by the masked site staff (except for the BCVA examiner) before the patient rec"
      },
      {
        "id": "fn_cond_9",
        "conditionType": "timing_before",
        "text": "i. Perform the assessments prior to dilating the eyes. Both refraction and BCVA will be assessed at every study visit for both eyes...",
        "footnoteId": "fn_9",
        "structuredCondition": "activity.before(Refraction, EyeDilation) AND activity.before(BCVA, EyeDilation)",
        "appliesToActivityIds": [
          "Refraction",
          "BCVA"
        ],
        "sourceText": "i. Perform the assessments prior to dilating the eyes. Both refraction and BCVA will be assessed at "
      },
      {
        "id": "fn_cond_10",
        "conditionType": "timing_before",
        "text": "j. The same method should be used throughout the study period. Perform measurements prior to dilating the eyes.",
        "footnoteId": "fn_10",
        "structuredCondition": "activity.before(Measurements, EyeDilation) AND method.consistency(true)",
        "appliesToActivityIds": [
          "Ocular Measurements"
        ],
        "sourceText": "j. The same method should be used throughout the study period. Perform measurements prior to dilatin"
      },
      {
        "id": "fn_cond_11",
        "conditionType": "timing_before",
        "text": "k. All women of childbearing potential... will have a urine pregnancy test performed at screening and prior to each study treatment...",
        "footnoteId": "fn_11",
        "structuredCondition": "IF patient.isWOCBP() THEN activity.perform(UrinePregnancyTest)",
        "appliesToActivityIds": [
          "Urine Pregnancy Test"
        ],
        "sourceText": "k. All women of childbearing potential... will have a urine pregnancy test performed at screening an"
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "l. The CRC will review SD-OCT (certain SS-OCT equipment may be acceptable; consult CRC) and CFP images obtained at screening...",
        "footnoteId": "fn_12",
        "structuredCondition": "imaging.review(SD-OCT, CFP) OR imaging.review(SS-OCT, CFP)",
        "appliesToActivityIds": [
          "SD-OCT",
          "CFP"
        ],
        "sourceText": "l. The CRC will review SD-OCT (certain SS-OCT equipment may be acceptable; consult CRC) and CFP imag"
      },
      {
        "id": "fn_cond_13",
        "conditionType": "general",
        "text": "m. Optional OCT-A in study eye to be conducted at sites with OCT-A capability and provided sites approve optional OCT-A sampling.",
        "footnoteId": "fn_13",
        "structuredCondition": "IF site.hasCapability(OCT-A) AND site.approves(OCT-A) THEN activity.optional(OCT-A)",
        "appliesToActivityIds": [
          "OCT-A"
        ],
        "sourceText": "m. Optional OCT-A in study eye to be conducted at sites with OCT-A capability and provided sites app"
      },
      {
        "id": "fn_cond_14",
        "conditionType": "timing_before",
        "text": "n. Obtain prior to FFA (if applicable) and prior to study treatment. Missed mandatory PK, PD, or ADA samples may be obtained at the next scheduled visit...",
        "footnoteId": "fn_14",
        "structuredCondition": "activity.before(Samples, FFA) AND activity.before(Samples, Treatment)",
        "appliesToActivityIds": [
          "PK",
          "PD",
          "ADA"
        ],
        "sourceText": "n. Obtain prior to FFA (if applicable) and prior to study treatment. Missed mandatory PK, PD, or ADA"
      },
      {
        "id": "fn_cond_15",
        "conditionType": "general",
        "text": "o. The finger-counting test should be conducted by the treatment administrator/unmasked investigator within approximately 15 minutes of study treatment...",
        "footnoteId": "fn_15",
        "structuredCondition": "activity.within(FingerCounting, Treatment, PT15M)",
        "appliesToActivityIds": [
          "Finger-counting test"
        ],
        "sourceText": "o. The finger-counting test should be conducted by the treatment administrator/unmasked investigator"
      },
      {
        "id": "fn_cond_16",
        "conditionType": "general",
        "text": "p. Postdose IOP measurement to be conducted in the study eye only at 30 (± 15) minutes by qualified personnel assigned to the unmasked role.",
        "footnoteId": "fn_16",
        "structuredCondition": "activity.after(IOP, Treatment, PT30M) AND tolerance(PT15M)",
        "appliesToActivityIds": [
          "Postdose IOP measurement"
        ],
        "sourceText": "p. Postdose IOP measurement to be conducted in the study eye only at 30 (± 15) minutes by qualified "
      },
      {
        "id": "fn_cond_17",
        "conditionType": "general",
        "text": "w. Concurrent ocular procedures (referenced in table)",
        "footnoteId": "fn_21",
        "structuredCondition": "activity.concurrent(OcularProcedures)",
        "appliesToActivityIds": [
          "Ocular Procedures"
        ],
        "sourceText": "w. Concurrent ocular procedures (referenced in table)"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Change from baseline in BCVA at Week 24",
        "endpointType": "Primary",
        "inputs": [
          "BCVA_Baseline",
          "BCVA_Week_24"
        ],
        "timeWindow": {
          "reference": "Baseline (Day 1)",
          "duration": "Week 24"
        },
        "algorithm": "BCVA_Week_24 - BCVA_Baseline",
        "successCriteria": "Non-inferiority of faricimab Q4W compared with aflibercept Q4W at a 1-sided 0.025 significance level; Superiority at a 2-sided 0.05 significance level.",
        "sourceText": "Change from baseline in BCVA at Week 24"
      },
      {
        "id": "ep_2",
        "name": "Secondary: Proportion of patients gaining >= 15 letters in BCVA",
        "endpointType": "Secondary",
        "inputs": [
          "BCVA_Baseline",
          "BCVA_Week_24"
        ],
        "timeWindow": {
          "reference": "Baseline (Day 1)",
          "duration": "Week 24"
        },
        "algorithm": "(Count of patients where (BCVA_Week_24 - BCVA_Baseline) >= 15) / Total patients in ITT population",
        "successCriteria": "Comparison of faricimab vs aflibercept through Week 24",
        "sourceText": "Proportion of patients gaining >=15 letters in BCVA from baseline at Week 24"
      },
      {
        "id": "ep_3",
        "name": "Secondary: Categorical BCVA Letter Gain",
        "endpointType": "Secondary",
        "inputs": [
          "BCVA_Baseline",
          "BCVA_Visit_X"
        ],
        "timeWindow": {
          "reference": "Baseline (Day 1)",
          "duration": "Through Week 24"
        },
        "algorithm": "Count of patients meeting thresholds (>=15, >=10, >=5, or >0 letters) / Total patients",
        "successCriteria": "Evaluation at specified timepoints through Week 24",
        "sourceText": "Proportion of patients gaining >=15, >=10, >=5, or >0 letters in BCVA from baseline at specified timepoints through Week 24"
      },
      {
        "id": "ep_4",
        "name": "Secondary: Change from baseline in BCVA at specified timepoints",
        "endpointType": "Secondary",
        "inputs": [
          "BCVA_Baseline",
          "BCVA_Visit_X"
        ],
        "timeWindow": {
          "reference": "Baseline (Day 1)",
          "duration": "Weeks 4 through 24"
        },
        "algorithm": "BCVA_Visit_X - BCVA_Baseline",
        "successCriteria": "Evaluation of faricimab vs aflibercept through Week 24",
        "sourceText": "Change from baseline in BCVA at specified timepoints through Week 24"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Change from baseline in BCVA at Week 24",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "BCVA"
        ],
        "derivationRule": "BCVA_at_Week_24 - BCVA_at_Baseline",
        "baselineDefinition": "Not explicitly defined in text; typically last non-missing value prior to first dose",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 24",
        "imputationRule": "Not specified in text",
        "unit": "letters"
      },
      {
        "id": "dv_2",
        "name": "Proportion of patients gaining >=15 letters in BCVA from baseline at Week 24",
        "variableType": "Categorical",
        "sourceVariables": [
          "BCVA"
        ],
        "derivationRule": "(BCVA_at_Week_24 - BCVA_at_Baseline) >= 15",
        "baselineDefinition": "Not explicitly defined in text",
        "baselineVisit": "Baseline",
        "analysisWindow": "Week 24",
        "imputationRule": "Not specified in text",
        "unit": "percentage"
      },
      {
        "id": "dv_3",
        "name": "Proportion of patients achieving >=84 letters in BCVA",
        "variableType": "Categorical",
        "sourceVariables": [
          "BCVA"
        ],
        "derivationRule": "BCVA_at_timepoint >= 84",
        "baselineDefinition": "Not applicable",
        "baselineVisit": "Not applicable",
        "analysisWindow": "Specified timepoints through Week 72",
        "imputationRule": "Not specified in text",
        "unit": "percentage"
      },
      {
        "id": "dv_4",
        "name": "Change from baseline in central subfield thickness (CST)",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "CST"
        ],
        "derivationRule": "CST_at_timepoint - CST_at_Baseline",
        "baselineDefinition": "Not explicitly defined in text",
        "baselineVisit": "Baseline",
        "analysisWindow": "Specified timepoints through Week 72",
        "imputationRule": "Not specified in text",
        "unit": "micrometers"
      },
      {
        "id": "dv_5",
        "name": "Change from baseline in NEI VFQ-25 composite score",
        "variableType": "Composite",
        "sourceVariables": [
          "NEI VFQ-25 items"
        ],
        "derivationRule": "Mean of subscale scores as defined by NEI VFQ-25 manual; Change = Score_at_timepoint - Score_at_Baseline",
        "baselineDefinition": "Not explicitly defined in text",
        "baselineVisit": "Baseline",
        "analysisWindow": "Specified timepoints through Week 72",
        "imputationRule": "Not specified in text",
        "unit": "score"
      },
      {
        "id": "dv_6",
        "name": "Change from Week 24 in BCVA",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "BCVA"
        ],
        "derivationRule": "BCVA_at_timepoint - BCVA_at_Week_24",
        "baselineDefinition": "Value at Week 24",
        "baselineVisit": "Week 24",
        "analysisWindow": "Week 24 through Week 72",
        "imputationRule": "Not specified in text",
        "unit": "letters"
      },
      {
        "id": "dv_7",
        "name": "Proportion of patients on a Q4W, Q8W, Q12W, or Q16W treatment interval",
        "variableType": "Categorical",
        "sourceVariables": [
          "Dosing Date",
          "PTI Dosing Regimen"
        ],
        "derivationRule": "Frequency of dosing at Week 72 based on PTI algorithm",
        "baselineDefinition": "Not applicable",
        "baselineVisit": "Not applicable",
        "analysisWindow": "Week 72",
        "imputationRule": "Not specified in text",
        "unit": "percentage"
      },
      {
        "id": "dv_8",
        "name": "Number of study drug injections received from Week 24 through Week 72",
        "variableType": "Custom",
        "sourceVariables": [
          "Injection Log"
        ],
        "derivationRule": "Sum of all injections administered between Week 24 and Week 72 inclusive",
        "baselineDefinition": "Not applicable",
        "baselineVisit": "Not applicable",
        "analysisWindow": "Week 24 to Week 72",
        "imputationRule": "Not specified in text",
        "unit": "count"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Randomization",
        "Treatment",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Randomization",
          "trigger": "Progress to Randomization"
        },
        {
          "fromState": "Randomization",
          "toState": "Treatment",
          "trigger": "Progress to Treatment"
        },
        {
          "fromState": "Treatment",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Randomization": "RANDOMIZATION",
        "Treatment": "TREATMENT",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Appendix",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 4.0,
            "unit": "g"
          }
        ],
        "sourceText": "............. 110 Appendix 2 Unscheduled Safety Assessment Visit..................................... 122 Appendix 3 Study Treatment Preparation................................................... 123 "
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "Faricimab (RO6867461)",
        "frequency": "Q4W",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "Part 1 (Weeks 0-20), followed by Part 2 (PTI Regimen)",
        "titrationSchedule": "Personalized Treatment Interval (PTI) regimen starting in Part 2 (Week 20+)"
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Active Comparator",
        "frequency": "Q4W",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "Part 1"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_2",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "Screening .............................................................................. 35 3.1.1.2 Re-Screening......................................................................... 36"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "Background on Retinal Vein Occlusion ................................. 24 1.2 Background on Faricimab...................................................... 25"
      },
      {
        "id": "visit_5",
        "visitName": "End of Study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "End of Study",
        "sourceText": "End of Study and Length of Study......................................... 42 3.3 Rationale for Study Design.................................................... 42"
      },
      {
        "id": "visit_7",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "Change from baseline in BCVA at Week 24 Secondary Efficacy Objectives The secondary efficacy objective for Part 1 of this study (i.e., through Week 24) is to evaluate"
      },
      {
        "id": "visit_llm_9",
        "visitName": "Week 24 to Week 72 (PTI Dosing)",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 9,
        "epoch": "Part 2 (PTI Regimen)"
      },
      {
        "id": "visit_3",
        "visitName": "Randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 6,
        "epoch": "Part 1 (Q4W Dosing)",
        "sourceText": "Randomization and Visit Schedule........................................ 36 3.1.2 Compliance with Study Visits, Handling of Missed"
      },
      {
        "id": "visit_11",
        "visitName": "Day 7",
        "targetDay": 7,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "Day 7 (3 days) evaluated by the masked investigator. At subsequent scheduled visits, patients will have predose safety assessments evaluated by the masked investigator prior to receiving study treatm"
      },
      {
        "id": "visit_llm_3",
        "visitName": "Week 4",
        "targetDay": 29,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 3,
        "targetWeek": 4,
        "epoch": "Part 1 (Q4W Dosing)"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Week 8",
        "targetDay": 57,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 4,
        "targetWeek": 8,
        "epoch": "Part 1 (Q4W Dosing)"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Week 12",
        "targetDay": 85,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 5,
        "targetWeek": 12,
        "epoch": "Part 1 (Q4W Dosing)"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Week 16",
        "targetDay": 113,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 6,
        "targetWeek": 16,
        "epoch": "Part 1 (Q4W Dosing)"
      },
      {
        "id": "visit_4",
        "visitName": "Week 20",
        "targetDay": 134,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "targetWeek": 20,
        "epoch": "Part 1 (Q4W Dosing)",
        "sourceText": "Week 20 ................................................................................ 40 3.1.4.3 Faricimab Interruption at Faricimab Dosing Visits"
      },
      {
        "id": "visit_6",
        "visitName": "Week 24",
        "targetDay": 162,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 13,
        "targetWeek": 24,
        "epoch": "Primary Endpoint / Transition to Part 2",
        "sourceText": "the primary endpoint at Week 24. Efficacy, safety, and pharmacokinetics of faricimab administered according to the personalized treatment interval (PTI) dosing regimen (i.e., from every 4 weeks [Q4W] "
      },
      {
        "id": "visit_12",
        "visitName": "Week 28",
        "targetDay": 190,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "targetWeek": 28,
        "sourceText": "by the IxRS, skipping the dose at Week 28. 3.1.4.3 Faricimab Interruption at Faricimab Dosing Visits Starting from"
      },
      {
        "id": "visit_10",
        "visitName": "Week 68",
        "targetDay": 470,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 15,
        "targetWeek": 68,
        "sourceText": "Week 68, a sham procedure will be administered during study visits at which (according to the PTI dosing regimen) no faricimab treatment is administered. Only one eye will be assigned as the study eye"
      },
      {
        "id": "visit_8",
        "visitName": "Week 72",
        "targetDay": 498,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 16,
        "targetWeek": 72,
        "sourceText": "Proportion of patients gaining 15 letters in BCVA from baseline at Week 72  Proportion of patients gaining 15, 10, 5, or 0 letters in BCVA from baseline at"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "Stratified block randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Baseline",
          "categories": [
            "Category 1",
            "Category 2"
          ],
          "isBlocking": false,
          "sourceText": "baseline bcva etdrs letter \nscore, as assessed on day 1 (55 letters vs"
        },
        {
          "id": "strat_llm_1",
          "name": "Baseline BCVA score",
          "categories": [
            "73 to 34 letters",
            "33 to 19 letters"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Region",
          "categories": [
            "United States and Canada",
            "Asia",
            "Rest of the World"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "Faricimab—F. Hoffmann-La Roche Ltd\n5/Protocol GR41984, Version 2\n3.1.2.2\nIxRS Reporting of Visual Acuity Score, \nStudy Treatment Interruption, and Missed Study \nTreatment Visits......................."
    }
  }
}